Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Diabetes Technology & Therapeutics|June 3, 2005
IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study designAndreas Pfützner, Eberhard Standl, Cloth Hohberg, et al.
Metabolism: Clinical and Experimental|March 24, 2007
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT StudyThomas Forst, Andreas Pfützner, Georg Lübben, et al.
Diabetes, Obesity & Metabolism|December 24, 2016
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic studyThomas Forst, Alexander Falk, Grit Andersen, et al.
Cardiovascular Diabetology|April 1, 2021
Report from the CVOT Summit 2020: new cardiovascular and renal outcomesOliver Schnell, Xavier Cos, Francesco Cosentino, et al.
Archives of Physiology and Biochemistry|November 4, 2009
Resolution of adiponectin oligomers in human plasma using free flow electrophoresisAude L Foucher, Kristina Hartmann, Monika Hauptmann, et al.
Diabetes Technology & Therapeutics|June 28, 2006
The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitusAndreas Pfützner, Babette Lorra, Michel R Abdollahnia, et al.
Journal of Diabetes Science and Technology|February 11, 2010
Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot studyPetra B Musholt, Thomas Schöndorf, Andreas Pfützner, et al.
Journal of Diabetes Science and Technology|February 10, 2011
Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitusJulia Pfützner, Juliane Hellhammer, Petra Musholt, et al.
Diabetes Care|November 6, 2016
Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal TrialJort Kropff, Pratik Choudhary, Sankalpa Neupane, et al.
Nephron Extra|June 29, 2012
Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren StudyJan Galle, Werner Kleophas, Frank Dellanna, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Diabetes Technology & Therapeutics|June 3, 2005
IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study designAndreas Pfützner, Eberhard Standl, Cloth Hohberg, et al.
Metabolism: Clinical and Experimental|March 24, 2007
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT StudyThomas Forst, Andreas Pfützner, Georg Lübben, et al.
Diabetes, Obesity & Metabolism|December 24, 2016
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic studyThomas Forst, Alexander Falk, Grit Andersen, et al.
Cardiovascular Diabetology|April 1, 2021
Report from the CVOT Summit 2020: new cardiovascular and renal outcomesOliver Schnell, Xavier Cos, Francesco Cosentino, et al.
Archives of Physiology and Biochemistry|November 4, 2009
Resolution of adiponectin oligomers in human plasma using free flow electrophoresisAude L Foucher, Kristina Hartmann, Monika Hauptmann, et al.
Diabetes Technology & Therapeutics|June 28, 2006
The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitusAndreas Pfützner, Babette Lorra, Michel R Abdollahnia, et al.
Journal of Diabetes Science and Technology|February 11, 2010
Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot studyPetra B Musholt, Thomas Schöndorf, Andreas Pfützner, et al.
Journal of Diabetes Science and Technology|February 10, 2011
Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitusJulia Pfützner, Juliane Hellhammer, Petra Musholt, et al.
Diabetes Care|November 6, 2016
Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal TrialJort Kropff, Pratik Choudhary, Sankalpa Neupane, et al.
Nephron Extra|June 29, 2012
Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren StudyJan Galle, Werner Kleophas, Frank Dellanna, et al.
Pageof 15